220 related articles for article (PubMed ID: 29602915)
1. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
2. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
3. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
4. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
[No Abstract] [Full Text] [Related]
6. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
8. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
9. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
10. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
11. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
Richter S; Wagner B; Celius EG
J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
[No Abstract] [Full Text] [Related]
12. A case of anaphylaxis to alemtuzumab.
Nye CJS; Wagner A; Kousin-Ezewu O; Jones JL; Coles AJ
J Neurol; 2019 Mar; 266(3):780-781. PubMed ID: 30715557
[No Abstract] [Full Text] [Related]
13. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
[TBL] [Abstract][Full Text] [Related]
14. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.
Croteau D; Flowers C; Kulick CG; Brinker A; Kortepeter CM
Neurology; 2018 May; 90(18):e1548-e1552. PubMed ID: 29602912
[TBL] [Abstract][Full Text] [Related]
15. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G
Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274
[No Abstract] [Full Text] [Related]
16. Clinical observation during alemtuzumab administration.
Allen CM; Feng JJ; Willis MD; McGinley M; Ontaneda D; Tallantyre EC; Evangelou N
Mult Scler Relat Disord; 2020 Jan; 37():101412. PubMed ID: 32172992
[No Abstract] [Full Text] [Related]
17. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
18. Case of alemtuzumab-related alopecia areata management in MS.
Chan JK; Traboulsee AL; Sayao AL
Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e516. PubMed ID: 30568994
[No Abstract] [Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Hoffman BM; Zeid NA; Alam U; Caress JB
Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
[TBL] [Abstract][Full Text] [Related]
20. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]